Flora Swaran J S, Pande Manisha, Mehta Ashish
Division of Pharmacology and Toxicology, Defence Research and Development Establishment, Jhansi Road, Gwalior 474002, India.
Chem Biol Interact. 2003 Jun 15;145(3):267-80. doi: 10.1016/s0009-2797(03)00025-5.
Ameliorative effects of few naturally occurring antioxidants like ascorbic acid (vitamin C), alpha-tocopherol (vitamin E) either alone or in combination with meso-2,3-dimercaptosuccinic acid (DMSA) or monoisoamyl DMSA (MiADMSA), on parameters indicative of oxidative stress in the liver, kidney, brain and blood of lead-exposed rats were studied. Male Wistar rats were exposed to 0.1% lead acetate in drinking water for 3 months and treated thereafter with DMSA or its analogue MiADMSA (50 mg/kg, intraperitoneally), either individually or in combination with vitamin E (5 mg/kg, intramuscularly) or vitamin C (25 mg/kg, orally) once daily for 5 days. The effects of these treatments in influencing the lead-induced alterations in haem synthesis pathway, hepatic, renal and brain oxidative stress and lead concentration from the soft tissues were investigated. Exposure to lead produced a significant inhibition of delta-aminolevulinic acid dehydratase (ALAD) activity from 8.44+/-0.26 in control animals to 1.76+/-0.32 in lead control, reduction in glutathione (GSH) from 3.56+/-0.14 to 2.57+/-0.25 and an increase in zinc protoporphyrin level from 62.0+/-3.9 to 170+/-10.7 in blood, suggesting altered haem synthesis pathway. Both the thiol chelators and the two vitamins were able to increase blood ALAD activity towards normal, however, GSH level responded favorably only to the two thiol chelators. The most prominent effect on blood ALAD activity was, however, observed when MiADMSA was co-administered with vitamin C (7.51+/-0.17). Lead exposure produced a significant depletion of hepatic GSH from 4.59+/-0.78 in control animals to 2.27+/-0.47 in lead controls and catalase activity from 100+/-3.4 to 22.1+/-0.25, while oxidized glutathione (GSSG; 0.34+/-0.05 to 2.05+/-0.25), thiobarbituric acid reactive substance (TBARS; 1.70+/-0.45 to 5.22+/-0.50) and glutathione peroxidase (GPx) levels (3.41+/-0.09 to 6.17+/-0.65) increased significantly, pointing to hepatic oxidative stress. Altered, reduced and oxidized GSH levels showed significant recovery after MiADMSA and DMSA administration while, vitamins E and C were effective in reducing GSSG and TBARS levels and increasing catalase activity. Administration of MiADMSA alone and the combined administration of vitamin C along with DMSA and MiADMSA were most effective in increasing hepatic GSH levels to 4.88+/-0.14, 4.09+/-0.12 and 4.30+/-0.06, respectively. Hepatic catalase also reached near normal level in animals co-administered vitamin C with DMSA or MiADMSA (82.5+/-4.5 and 84.2+/-3.5, respectively). Combined treatments with vitamins and the thiol chelators were also able to effectively reduce lead-induced decrease in renal catalase activity and increase in TBARS and GPx level. Combination therapy, however, was unable to provide an effective reversal in the altered parameters indicative of oxidative stress in different brain regions, except in catalase activity. The result also suggests a beneficial role of vitamin E when administered along with the thiol chelators (particularly with MiADMSA) in reducing body lead burden. Blood lead concentration was reduced from 13.3+/-0.11 in lead control to 0.3+/-0.01 in MiADMSA plus vitamin E-treated rats. Liver and kidney lead concentration also showed a most prominent decrease in MiADMSA plus vitamin E co-administered rats (5.29+/-0.16 to 0.63+/-0.02 and 14.1+/-0.21 to 1.51+/-0.13 in liver and kidney, respectively). These results thus suggest that vitamin C administration during chelation with DMSA/MiADMSA was significantly beneficial in reducing oxidative stress however, it had little or no additive effect on the depletion of lead compared with the effect of chelators alone. Thus, the co-administration of vitamin E during chelation treatment with DMSA or MiADMSA could be recommended for achieving optimum effects of chelation therapy.
研究了几种天然抗氧化剂,如抗坏血酸(维生素C)、α-生育酚(维生素E)单独或与内消旋-2,3-二巯基丁二酸(DMSA)或单异戊基DMSA(MiADMSA)联合使用,对铅暴露大鼠肝脏、肾脏、大脑和血液中氧化应激指标的改善作用。雄性Wistar大鼠饮用含0.1%醋酸铅的水3个月,此后用DMSA或其类似物MiADMSA(50mg/kg,腹腔注射)单独或与维生素E(5mg/kg,肌肉注射)或维生素C(25mg/kg,口服)联合治疗,每日1次,共5天。研究了这些治疗对铅诱导的血红素合成途径改变、肝脏、肾脏和大脑氧化应激以及软组织中铅浓度的影响。铅暴露导致δ-氨基乙酰丙酸脱水酶(ALAD)活性从对照动物的8.44±0.26显著抑制至铅对照的1.76±0.32,血液中谷胱甘肽(GSH)从3.56±0.14降至2.57±0.25,锌原卟啉水平从62.0±3.9升至170±10.7,提示血红素合成途径改变。硫醇螯合剂和两种维生素均能使血液ALAD活性恢复正常,但GSH水平仅对两种硫醇螯合剂有良好反应。然而,当MiADMSA与维生素C联合给药时,对血液ALAD活性的影响最为显著(7.51±0.17)。铅暴露导致肝脏GSH从对照动物的4.59±0.78显著耗竭至铅对照的2.27±0.47,过氧化氢酶活性从100±3.4降至22.1±0.25,而氧化型谷胱甘肽(GSSG;0.34±0.05至2.05±0.25)、硫代巴比妥酸反应性物质(TBARS;1.70±0.45至5.22±0.50)和谷胱甘肽过氧化物酶(GPx)水平(3.41±0.09至6.17±0.65)显著增加,表明肝脏存在氧化应激。MiADMSA和DMSA给药后,GSH水平的改变、降低和氧化均有显著恢复,而维生素E和C能有效降低GSSG和TBARS水平并增加过氧化氢酶活性。单独给予MiADMSA以及维生素C与DMSA和MiADMSA联合给药在将肝脏GSH水平分别提高至4.88±0.14、4.09±0.12和4.30±0.06方面最为有效。在维生素C与DMSA或MiADMSA联合给药的动物中,肝脏过氧化氢酶也接近正常水平(分别为82.5±4.5和84.2±3.5)。维生素与硫醇螯合剂的联合治疗也能有效减轻铅诱导的肾脏过氧化氢酶活性降低以及TBARS和GPx水平升高。然而,联合治疗除了过氧化氢酶活性外,无法有效逆转不同脑区氧化应激指标的改变。结果还表明,维生素E与硫醇螯合剂(特别是与MiADMSA)联合给药在降低体内铅负荷方面具有有益作用。血液铅浓度从铅对照的13.3±0.11降至MiADMSA加维生素E治疗大鼠的0.3±0.01。在MiADMSA加维生素E联合给药的大鼠中,肝脏和肾脏铅浓度也显著降低(肝脏从5.29±0.16降至0.63±0.02,肾脏从14.1±0.21降至1.51±0.13)。因此,这些结果表明,在与DMSA/MiADMSA螯合治疗期间给予维生素C在减轻氧化应激方面具有显著益处,然而,与单独螯合剂的作用相比,它对铅的消耗几乎没有或没有附加作用。因此,在与DMSA或MiADMSA螯合治疗期间联合给予维生素E可推荐用于实现螯合治疗效果的最优化。